- Home
- AIMD vs NEUP Comparison
AIMD vs NEUP Comparison
Compare AIMD & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- NEUP
- Stock Information
- Founded
- AIMD 1984
- NEUP 1996
- Country
- AIMD United States
- NEUP United States
- Employees
- AIMD N/A
- NEUP N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- AIMD Health Care
- NEUP
- Exchange
- AIMD Nasdaq
- NEUP Nasdaq
- Market Cap
- AIMD 11.9M
- NEUP 12.7M
- IPO Year
- AIMD N/A
- NEUP N/A
- Fundamental
- Price
- AIMD $2.33
- NEUP $7.59
- Analyst Decision
- AIMD
- NEUP Strong Buy
- Analyst Count
- AIMD 0
- NEUP 1
- Target Price
- AIMD N/A
- NEUP $21.00
- AVG Volume (30 Days)
- AIMD 134.7K
- NEUP 42.2K
- Earning Date
- AIMD 08-15-2025
- NEUP 08-15-2025
- Dividend Yield
- AIMD N/A
- NEUP N/A
- EPS Growth
- AIMD N/A
- NEUP N/A
- EPS
- AIMD N/A
- NEUP 0.00
- Revenue
- AIMD $106,207.00
- NEUP $15,662,715.00
- Revenue This Year
- AIMD N/A
- NEUP N/A
- Revenue Next Year
- AIMD N/A
- NEUP N/A
- P/E Ratio
- AIMD N/A
- NEUP $4,502.65
- Revenue Growth
- AIMD 13.38
- NEUP N/A
- 52 Week Low
- AIMD $2.00
- NEUP $2.90
- 52 Week High
- AIMD $5.00
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- AIMD 36.64
- NEUP N/A
- Support Level
- AIMD $2.40
- NEUP N/A
- Resistance Level
- AIMD $2.66
- NEUP N/A
- Average True Range (ATR)
- AIMD 0.19
- NEUP 0.00
- MACD
- AIMD -0.04
- NEUP 0.00
- Stochastic Oscillator
- AIMD 11.77
- NEUP 0.00
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.